Nuclear Antibodies
Also known as: ANA
Antinuclear antibodies are associated with a variety of autoimmune and non autoimmune conditions. ANAs may be used as a screening test for connective tissue disease (CTDs), and are a sensitive marker of systemic lupus erythematosus; occurring in virtually all patients with untreated disease. A negative ANA on HEp-2 cells effectively excludes untreated SLE. Presence of ANAs in significant titre (>1/80) is not specific for SLE, occurring in up to 15 - 50% of patients with other autoimmune diseases e.g. rheumatoid arthritis, scleroderma, Sjogren's, dermatomyositis. The ANA titre is of little value in monitoring SLE disease activity, as the antibodies have an in-vivo half life of 3 - 4 weeks.
Specimen requirements
Serum - 1ml
Cost
Price on application
Laboratory turnaround time
3 days
Laboratory method
Indirect Immunofluorescence on Hep-2 Cells
Assay interferences
Microbially contaminated, heat-treated samples should not be used.
Grossly haemolysed, icteric or lipaemic specimens should be avoided. Plasma is contraindicated samples are not validated for this assay.
Reference range/units
Titre with pattern identified
Normal Range = 0 - 1/80 titre
Associated tests
- ENA Screen
- Autoantibody Screen
- dsDNA
Sample stability
3 weeks at 2-8ÂșC
Shipping and storage
UK and Ireland
Ambient temperature and first class post. Hays DX users please enquire via email below.
International
Ambient temperature if courier will deliver within 72 hours otherwise consider refrigerated transport. Freezing is not a requirement.
Ensure delivery Monday to Friday 09:00 - 17:30.
Further information and contact details
For further information, email immunologylab.enquiries@ouh.nhs.uk
Last reviewed:13 September 2022